Macrophages as predictors and new targets for immunotherapy in colorectal cancer

Abstract

Immunotherapy is a promising treatment strategy for treating colorectal cancer (CRC). Despite significant advances in this field, resistance and low efficacy of immunotherapy remain a principal problem. One of the most important factors affecting the response to immunotherapy is the tumor microenvironment (TME). Among the components of the TME, tumor-associated macrophages (TAMs) are key immune cells involved in cancer progression by stimulating tumor cell proliferation, angiogenesis, epithelial-mesenchymal transition, metastasis, and tumor immune evasion. This review presents currently investigated combination therapy based on the immune checkpoint inhibitors and inhibitors of diverse components of the TME, including TAMs, that can potentially increase the effectiveness of CRC treatment. Therapeutic efficacy, together with the functional activity of TAMs, is estimated in multiple preclinical data obtained with diverse in vitro and in vivo models. Ongoing clinical trials demonstrated the association of treatment effectiveness with TAM phenotypes and functions.

References

[1] Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025; 24: 136.

[2] Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem. 2011; 112: 1969-77.

[3] Sharma RK, Chheda ZS, Jala VR, Haribabu B. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. Expert Rev Vaccines. 2015; 14: 537-49.

[4] Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8⁺ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021; 124: 359-67.

[5] Oh DY, Fong L. Cytotoxic CD4⁺ T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021; 54: 2701-11.

[6] Elorbany S, Berlato C, Carnevalli LS, Maniati E, Barry ST, Wang J, et al. Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer. Nat Commun. 2024; 15: 10144.

[7] Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021; 18: 85-100.

[8] Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020; 124: 109821.

[9] Xia W, Zhang X, Wang Y, Huang Z, Guo X, Fang L. Progress in targeting tumor-associated macrophages in cancer immunotherapy. Front Immunol. 2025; 16: 1658795.

[10] Kzhyshkowska J, Shen J, Larionova I. Targeting of TAMs: can we be more clever than cancer cells? Cell Mol Immunol. 2024; 21: 1376-409.

[11] Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, et al. Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. Front Oncol. 2020; 10: 566511.

[12] Larionova I, Patysheva M, Iamshchikov P, Kazakova E, Kazakova A, Rakina M, et al. PFKFB3 overexpression in monocytes of patients with colon but not rectal cancer programs pro-tumor macrophages and is indicative for higher risk of tumor relapse. Front Immunol. 2023; 13: 1080501.

[13] Shmakova E, Sudarskikh T, Shalygina K, Chagovets V, Starodubtseva N, Tokareva A, et al. Inhibition of PFKFB3 in Macrophages Has a Dual Effect on Tumor-Regulating Lipid Metabolism. Int J Mol Sci. 2025; 27: 217.

[14] Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018; 233: 6425-40.

[15] Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 2017; 15: 53.

[16] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022; 21: 799-820.

[17] Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020; 11: 583084.

[18] Gao J, Liang Y, Wang L. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022; 13: 888713.

[19] Li W, Zhang X, Wu F, Zhou Y, Bao Z, Li H, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019; 10: 918.

[20] Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019; 8: 4709-21.

[21] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[22] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021; 14: 101174.

[23] Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14: 89-103.

[24] Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011; 135: 698-703.

[25] Kim Y, Wen X, Bae JM, Kim JH, Cho NY, Kang GH. The distribution of intratumoral macrophages correlates with molecular phenotypes and impacts prognosis in colorectal carcinoma. Histopathology. 2018; 73: 663-71.

[26] Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350-6.

[27] Luo Q, Quan Y, Liu W, Wu Z, Qiu W, Liang W, et al. Seed and Soil: Consensus Molecular Subgroups (CMS) and Tumor Microenvironment Features Between Primary Lesions and Metastases of Different Organ Sites in Colorectal Cancer. Cancer Manag Res. 2024; 16: 225-43.

[28] Leonard NA, Corry SM, Reidy E, Egan H, O’Malley G, Thompson K, et al. Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling. iScience. 2024; 27: 110701.

[29] Høye E, Kanduri C, Torgunrud A, Lorenz S, Edwin B, Larsen SG, et al. Enrichment of Cancer-Associated Fibroblasts, Macrophages, and Up-Regulated TNF-α Signaling in the Tumor Microenvironment of CMS4 Colorectal Peritoneal Metastasis. Cancer Med. 2025; 14: e70521.

[30] Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, et al. Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018; 19: 2577.

[31] Jafarov S, Link KH. Colon and rectal cancer are different tumor entities according to epidemiology, carcinogenesis, molecular- and tumor biology, primary and secondary prevention: preclinical evidence. Siberian J Onc. 2018; 17: 88-98. Russian.

[32] Feier CVI, Grama F, Moise GV, Vonica RC, Gaborean V, Faur AM, et al. Colorectal Cancer-One Disease, Two Fires: Distinct Inflammatory Landscapes in Colon and Rectal Cancer. Diagnostics (Basel). 2025; 15: 2387.

[33] Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010; 11: 19.

[34] Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study. BMC Cancer. 2001; 1: 7.

[35] Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 2001; 195: 171-8.

[36] Li JN, Zhao L, Wu J, Wu B, Yang H, Zhang HH, et al. Differences in gene expression profiles and carcinogenesis pathways between colon and rectal cancer. J Dig Dis. 2012; 13: 24-32.

[37] Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-7.

[38] Hsu YL, Lin CC, Jiang JK, Lin HH, Lan YT, Wang HS, et al. Clinicopathological and molecular differences in colorectal cancer according to location. Int J Biol Markers. 2019; 34: 47-53.

[39] Ma SX, Li L, Cai H, Guo TK, Zhang LS. Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review. World J Clin Oncol. 2023; 14: 81-8.

[40] Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024; 9: 274.

[41] Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022; 15: 95.

[42] Nicolini A, Ferrari P. Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Front Immunol. 2024; 15: 1353787.

[43] Yu B, Kang J, Lei H, Li Z, Yang H, Zhang M. Immunotherapy for colorectal cancer. Front Immunol. 2024; 15: 1433315.

[44] Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016; 11: 967-76.

[45] Mohammadi M, Mehrzad J, Delirezh N, Abdollahi A. Chronic Inflammation and Its Role in Colorectal Cancer Development. Oncogen. 2022; 5: 24.

[46] Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology. 2022; 162: 715-30.e3.

[47] Burgos-Molina AM, Téllez Santana T, Redondo M, Bravo Romero MJ. The Crucial Role of Inflammation and the Immune System in Colorectal Cancer Carcinogenesis: A Comprehensive Perspective. Int J Mol Sci. 2024; 25: 6188.

[48] El Omari N, El Fessikh M, Aboulaghras S, Bakrim S, Khalid A, Abdalla AN, et al. The role of inflammation in colorectal Cancer and the preventive potential of natural compounds. J Funct Foods. 2025; 129: 106857.

[49] Zhang M, Li X, Zhang Q, Yang J, Liu G. Roles of macrophages on ulcerative colitis and colitis-associated colorectal cancer. Front Immunol. 2023; 14: 1103617.

[50] Wang H, Tian T, Zhang J. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. Int J Mol Sci. 2021; 22: 8470.

[51] Blagov A, Shakhpazyan N, Maltseva O, Korchagina E, Orekhov A. Chronic inflammation in the development of colorectal cancer: pathological model and therapeutic targets. Cell Mol Biol (Noisy-le-grand). 2025; 71: 101-9.

[52] Shin AE, Tesfagiorgis Y, Larsen F, Derouet M, Zeng PYF, Good HJ, et al. F4/80⁺Ly6C^high Macrophages Lead to Cell Plasticity and Cancer Initiation in Colitis. Gastroenterology. 2023; 164: 593-609.e13.

[53] Gulubova M, Ananiev J, Yovchev Y, Julianov A, Karashmalakov A, Vlaykova T. The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients’ survival. J Mol Histol. 2013; 44: 679-92.

[54] Nakayama Y, Nagashima N, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res. 2002; 22: 4291-6.

[55] Koelzer VH, Canonica K, Dawson H, Sokol L, Karamitopoulou-Diamantis E, Lugli A, et al. Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. Oncoimmunology. 2015; 5: e1106677.

[56] Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007; 13: 1472-9.

[57] Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012; 7: e47045.

[58] Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019; 18: 64.

[59] Feng Q, Chang W, Mao Y, He G, Zheng P, Tang W, et al. Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. Clin Cancer Res. 2019; 25: 3896-907.

[60] Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer. 2009; 125: 1826-31.

[61] Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundström J, Salmi M, et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer. 2012; 131: 864-73.

[62] Kazakova E, Rakina M, Sudarskikh T, Iamshchikov P, Tarasova A, Tashireva L, et al. Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancers. Front Oncol. 2023; 13: 1058337.

[63] Edin S, Wikberg ML, Rutegård J, Oldenborg PA, Palmqvist R. Phenotypic skewing of macrophages in vitro by secreted factors from colorectal cancer cells. PLoS One. 2013; 8: e74982.

[64] Popēna I, Ābols A, Saulīte L, Pleiko K, Zandberga E, Jēkabsons K, et al. Effect of colorectal cancer-derived extracellular vesicles on the immunophenotype and cytokine secretion profile of monocytes and macrophages. Cell Commun Signal. 2018; 16: 17.

[65] Zhang Y, Zhao Y, Li Q, Wang Y. Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment. Front Immunol. 2021; 12: 685978.

[66] Treatment of Colon Cancer, by Stage [Internet]. American Cancer Society, Inc.; c2026 [cited 2026 Jan 20]. Available from: https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/by-stage-colon.html

[67] Treatment of Rectal Cancer, by Stage [Internet]. American Cancer Society, Inc.; c2026 [cited 2026 Jan 20]. Available from: https://www.cancer.org/cancer/types/colon-rectal-cancer/treating/by-stage-rectum.html

[68] Kciuk M, Wanke K, Kruczkowska W, Marciniak B, Kontek R. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules. 2025; 30: 2686.

[69] Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities. Front Immunol. 2022; 13: 795972.

[70] Ji K, Jia H, Liu Z, Yu G, Wen R, Zhang T, et al. New insight in immunotherapy and combine therapy in colorectal cancer. Front Cell Dev Biol. 2025; 12: 1453630.

[71] Yan S, Wang W, Feng Z, Xue J, Liang W, Wu X, et al. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges. Front Immunol. 2024; 15: 1403533.

[72] Yoon J, Moon H, Jeon Y, Choe S, Yoon H. Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines. Int J Mol Sci. 2025; 26: 4559.

[73] FDA Approval Likely to Change Initial Treatment for Some People with Advanced Colorectal Cancer [Internet]. National Cancer Institute; [cited 2026 Jan 20]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-nivolumab-ipilimumab-dmmr-colorectal-cancer

[74] Underwood PW, Ruff SM, Pawlik TM. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells. 2024; 13: 245.

[75] Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al.; KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23: 659-70.

[76] Hosokawa A, Yamada R, Otsuki Y, Tamura H, Ichihara A, Fukushima T, et al. Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer. Anticancer Res. 2025; 45: 5069-76.

[77] André T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025; 405: 383-95.

[78] Wu X, Lan X, Hu W, Zhang W, Lai X, Xu S, et al. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunol Immunother. 2021; 70: 3235-48.

[79] Li R, Lin YP, Shen X, Guo JY, Zhang Y, Tang JD, et al. Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability. Front Oncol. 2025; 15: 1636122.

[80] Chen L, Jiang X, Li Y, Zhang Q, Li Q, Zhang X, et al. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clin Immunol. 2022; 237: 108962.

[81] Zalila-Kolsi I, Dhieb D, Osman HA, Mekideche H. The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions. Biology (Basel). 2025; 14: 251.

[82] Chen Y, Liu X, Chen J, Kuang L, Zhang N, Li D, et al. Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8⁺ T cells. J Immunother Cancer. 2025; 13:e013027.

[83] Xiang J, Wang J, Xiao H, Huang C, Wu C, Zhang L, et al. Targeting tumor-associated macrophages in colon cancer: mechanisms and therapeutic strategies. Front Immunol. 2025; 16: 1573917.

[84] Vanmeerbeek I, Naulaerts S, Sprooten J, Laureano RS, Govaerts J, Trotta R, et al. Targeting conserved TIM3⁺VISTA⁺ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Sci Adv. 2024; 10: eadm8660.

[85] Yerolatsite M, Torounidou N, Amylidi A, Zarkavelis G, Hadjigeorgiou L, Lampri E, et al. The role of tumor-associated macrophages and PD-1/PD-L1 networking in colorectal cancer. Contemp Oncol (Pozn). 2025; 29: 123-30.

[86] Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024; 8: 31.

[87] Fumet JD, Latour C, Nuttin L, Derangère V, Ilie A, Russo P, et al. Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer. Cancer Res. 2026; 86: 785-801.

[88] Kim CW, Chon HJ, Kim C. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers (Basel). 2021; 13: 4906.

[89] Chen TW, Hung WZ, Chiang SF, Chen WT, Ke TW, Liang JA, et al. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett. 2022; 543: 215795.

[90] Chen X, Li W, Lei X, Li Z, Guo Q, Ma X, et al. Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure. Front Oncol. 2024; 14: 1429095.

[91] Al Zein M, Boukhdoud M, Shammaa H, Mouslem H, El Ayoubi LM, Iratni R, et al. Immunotherapy and immunoevasion of colorectal cancer. Drug Discov Today. 2023; 28: 103669.

[92] Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F, et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. 2021; 40: 288.

[93] Zhan Y, Xu J, Zhang Z, Hu Y, Li Y, Qian J, et al. Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. Cancer Commun (Lond). 2025; 45: 1203-28.

[94] Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, et al. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell. 2020; 182: 886-900.e17.

[95] Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, et al. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block “eat-me” signal. Signal Transduct Target Ther. 2023; 8: 312.

[96] Tran TT, Sánchez-Zuno GA, Osmani L, Caulfield J, Valdez CN, Piecychna M, et al. Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight. 2025; 10: e191539.

[97] Kim M, Min YK, Jang J, Park H, Lee S, Lee CH. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. J Immunother Cancer. 2021; 9: e002503.

[98] Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer. 2023; 22: 131.

[99] Zhang H, Ren Y, Wang F, Tu X, Tong Z, Liu L, et al. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Ther. 2024; 31: 1412-26.

[100] Li Y, Shen Z, Chai Z, Zhan Y, Zhang Y, Liu Z, et al. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity. Gut. 2023; 72: 2307-20.

[101] Gao G, Liao W, Shu P, Ma Q, He X, Zhang B, et al. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor. J Immunother Cancer. 2023; 11: e006343.

[102] Zhu M, Bai L, Liu X, Peng S, Xie Y, Bai H, et al. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages. J Immunother Cancer. 2022; 10: e005610.

[103] Chen JS, Hsieh YC, Chou CH, Wu YH, Yang MH, Chu SH, et al. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. Int J Mol Sci. 2022; 23: 10677.

[104] Zhao M, Zhou L, Zhang Q, Wang M, Dong Y, Wang Y, et al. Targeting MAPK14 by Lobeline Upregulates Slurp1-Mediated Inhibition of Alternative Activation of TAM and Retards Colorectal Cancer Growth. Adv Sci (Weinh). 2025; 12: e2407900.

[105] Chun J, Park SM, Lee M, Ha IJ, Jeong MK. The Sesquiterpene Lactone-Rich Fraction of Inula helenium L. Enhances the Antitumor Effect of Anti-PD-1 Antibody in Colorectal Cancer: Integrative Phytochemical, Transcriptomic, and Experimental Analyses. Cancers (Basel). 2023; 15: 653.

[106] Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545: 495-9.

[107] Shimizu D, Yuge R, Kitadai Y, Ariyoshi M, Miyamoto R, Hiyama Y, et al. Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts. Int J Mol Sci. 2024; 25: 7001.

[108] Dang T, Guan X, Cui L, Ruan Y, Chen Z, Zou H, et al. Epigenetics and immunotherapy in colorectal cancer: progress and promise. Clin Epigenetics. 2024; 16: 123.

[109] Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W, et al. The epigenetic hallmarks of immune cells in cancer. Mol Cancer. 2025; 24: 66.

[110] Zhang P, Du Y, Bai H, Wang Z, Duan J, Wang X, et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 2022; 20: 435.

[111] Kovalovsky D, Noonepalle S, Suresh M, Kumar D, Berrigan M, Gajendran N, et al. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy. Sci Adv. 2024; 10: eadp3687.

[112] Jiang W, Guan B, Sun H, Mi Y, Cai S, Wan R, et al. WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis. Nat Commun. 2025; 16: 1429.

[113] Liu F, Ran F, He H, Chen L. Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage. Arch Immunol Ther Exp (Warsz). 2020; 68: 33.

[114] Zhang G, Pan J, Xu X, Nie S, Lu L, Jing Y, et al. Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites. Int J Biol Macromol. 2025; 310: 143323.

[115] Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z, et al. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater. 2021; 135: 567-81.

[116] Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet JD, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019; 7: 1958-69.

[117] Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, et al. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. J Immunother Cancer. 2024; 12:e008210.

[118] Bortolomeazzi M, Keddar MR, Montorsi L, Acha-Sagredo A, Benedetti L, Temelkovski D, et al. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Gastroenterology. 2021; 161: 1179-93.

[119] Phillips MJ, Alese OB, Horvat NK, Greene E, Gbolahan OB, Coleman K, et al. XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial. Oncoimmunology. 2025; 14: 2475620.

[120] Wang L, Diao YZ, Ma XF, Luo YS, Guo QJ, Chen XQ. Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy. World J Gastrointest Surg. 2024; 16: 3277-87.

[121] Haag GM, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, et al. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer-The PICCASSO phase I trial. Eur J Cancer. 2022; 167: 112-22.

[122] Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024; 30: 1035-43.

[123] André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al.; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383: 2207-18.

[124] Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020; 38: 2053-61.

[125] Kawazoe A, Itahashi K, Yamamoto N, Kotani D, Kuboki Y, Taniguchi H, et al. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clin Cancer Res. 2021; 27: 6709-15.

[126] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15: 550.

[127] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26: 139-40.

[128] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102: 15545-50.

[129] Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25: 25-9.

[130] Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28: 27-30.

[131] Croft D, O’Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011; 39: D691-7.

[132] Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023; 51: D870-6.

[133] Li W, Wang L, Wu Y, Yuan Z, Zhou J. Weighted gene coexpression network analysis to identify key modules and hub genes associated with atrial fibrillation. Int J Mol Med. 2020; 45: 401-16.

[134] Singhania A, Verma R, Graham CM, Lee J, Tran T, Richardson M, et al. A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat Commun. 2018; 9: 2308.

[135] Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, et al. Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel). 2019; 12: 37.

[136] Zeng F, Shi M, Xiao H, Chi X. WGCNA-Based Identification of Hub Genes and Key Pathways Involved in Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2021; 2021: 5633211.

[137] Wang C, Chen J, Wang X, Liang X, Yu S, Gui Y, et al. Identifying Potential Diagnostic and Therapeutic Targets for Infantile Hemangioma Using WGCNA and Machine Learning Algorithms. Biochem Genet. 2025; 63: 3968-88.

[138] Tian Z, He W, Tang J, Liao X, Yang Q, Wu Y, et al. Identification of Important Modules and Biomarkers in Breast Cancer Based on WGCNA. Onco Targets Ther. 2020; 13: 6805-17.

[139] Kong Y, Feng ZC, Zhang YL, Liu XF, Ma Y, Zhao ZM, et al. Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis. Front Immunol. 2020; 11: 1281.

[140] Wang T, Dai L, Shen S, Yang Y, Yang M, Yang X, et al. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Front Immunol. 2022; 13: 843408.

[141] Zhang H, Luo YB, Wu W, Zhang L, Wang Z, Dai Z, et al. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Comput Struct Biotechnol J. 2021; 19: 4603-18.

[142] Patysheva MR, Iamshchikov PS, Fedorenko AA, Bragina OD, Vostrikova MA, Garbukov EY, et al. Single-cell transcriptomic profiling of immune landscape in triple-negative breast cancer during neoadjuvant chemotherapy. NPJ Syst Biol Appl. 2025; 11: 72.

[143] Larionova I, Iamshchikov P, Kazakova A, Rakina M, Menyalo M, Enikeeva K, et al. Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma. Front Immunol. 2024; 15: 1414716.

[144] Rakina M, Larionova I, Kzhyshkowska J. Macrophage diversity in human cancers: New insight provided by single-cell resolution and spatial context. Heliyon. 2024; 10:e28332.

[145] Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017; 14: 1083-6.

[146] Mo Z, Liu D, Chen Y, Luo J, Li W, Liu J, et al. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4⁺ T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma. J Transl Med. 2022; 20: 466.

[147] Lou J, Luo G, Zhao L, Zhang H. CONSORT article: Single-cell sequencing analysis revealed CMKLR1⁺ macrophage as a subpopulation of macrophage with tumor-suppressive characteristics in oral squamous cell carcinoma. Medicine (Baltimore). 2024; 103:e39399.

[148] Kamimoto K, Stringa B, Hoffmann CM, Jindal K, Solnica-Krezel L, Morris SA. Dissecting cell identity via network inference and in silico gene perturbation. Nature. 2023; 614: 742-51.

[149] Liu Z, Bian X, Luo L, Björklund ÅK, Li L, Zhang L, et al. Spatiotemporal single-cell roadmap of human skin wound healing. Cell Stem Cell. 2025; 32: 479-98. e8.

[150] Amrute JM, Zhu A, Pai YL, Hector-Greene M, An Y, Kim KR, et al. Targeting RUNX1 in Macrophages Facilitates Cardiac Recovery. bioRxiv 665779 [Preprint]. 2025 [cited 2026 Jan 20]. Available from: https://www.biorxiv.org/content/10.1101/2025.07.25.665779v1

[151] Coulton A, Murai J, Qian D, Thakkar K, Lewis CE, Litchfield K. Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nat Commun. 2024; 15: 5665.

[152] Nasir I, McGuinness C, Poh AR, Ernst M, Darcy PK, Britt KL. Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies. Trends Immunol. 2023; 44: 971-85.

[153] Ma Ry, Black A, Qian Bz. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022; 43: 546-63.

[154] Yu X, Yang C. Heterogeneity of Innate Immunity. Organ Med. 2025; 2: 123-32.

[155] de Jong M, Maina T. Of mice and humans: are they the same?--Implications in cancer translational research. J Nucl Med. 2010; 51: 501-4.

[156] Hiroshima Y, Zhang Y, Zhang N, Uehara F, Maawy A, Murakami T, et al. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. Anticancer Res. 2015; 35: 697-701.

[157] Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, et al. Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy. Sci Rep. 2019; 9: 11117.

[158] Sheng Y, Xie Z, Wang J, Yang X, Yao M, Qian W, et al. Impact of Subcutaneous Versus Orthotopic Implantations on Patient-Derived Xenograft Transcriptomic Profiles. Cancer Res Commun. 2025; 5: 871-80.

[159] Han R, Zhao W, Gu X, Gao X, Yang Yg, Zhang X. Different tumorigenicity and distinct metastasis and gene signature between orthotopic and subcutaneous neuroblastoma xenografted mice. Aging (Albany NY). 2022; 14: 1932-40.

[160] Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008; 1: 78-82.

[161] Tian H, Lyu Y, Yang Yg, Hu Z. Humanized Rodent Models for Cancer Research. Front Oncol. 2020; 10: 1696.